Aileron Therapeutics, INC 10-Q quarterly reports

Rein Therapeutics reports continued net losses and an accumulated deficit, though it has sufficient cash to fund operations into early 2028 and is advancing its LTI-03 Phase 2 trial.

Rein Therapeutics reports progress on LTI-03 Phase 2 trial and significant capital raise, aiming to extend runway into Q1 2028.

Rein Therapeutics announced the FDA lifted the clinical hold on its lead IPF candidate LTI-03, but disclosed substantial doubt about its ability to continue as a going concern past December 2025 without additional funding.

Rein Therapeutics reported a clinical hold on its lead LTI-03 trial, raised capital through new agreements, and disclosed substantial doubt about its ability to continue as a going concern.

Rein Therapeutics reports a net loss of $5.5 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Aileron Therapeutics announced positive topline data from its Phase 1b clinical trial of LTI-03 for IPF, while also expressing substantial doubt about its ability to continue as a going concern due to insufficient cash reserves.

Aileron Therapeutics reported its financial results for the second quarter of 2024, highlighting progress in its clinical programs and a strategic shift in resource allocation.

Aileron Therapeutics reported its first quarter 2024 financial results, highlighted by positive trends in a Phase 1b clinical trial for LTI-03 and a recent capital raise.